Ecotest ABC+RSV Rapid Antigen Pen

RSV, Influenza A+B & COVID-19 Nasal Test

The RSV, Influenza A/B & COVID-19 Antigen Nasal Test Kit is an in-vitro immunoassay that detects viral nucleocapsid proteins of SARS-CoV-2, Influenza A virus, Influenza B virus and viral antigens of respiratory syncytial virus (RSV) from a simple nasal swab. Ideal for medical practice or home testing, the user-friendly and easy-to-administer design can help in diagnosing a range of respiratory viruses, giving quick and accurate results.

Versatile test with flexible fulfilment

Ecotest RSV + ABC Tests feature a patented design and are convenient to store, stack or display, as well as easy to use and dispose of. Our tests are ideal for government, corporate or private applications, and are available for delivery in custom order quantities of 2, 5 and 20 packs, to suit your distribution needs.

Order now

Convenient 4-in-1 viral testing

Designed to be non-invasive and easy to self-administer, the Ecotest RSV + ABC Test Pen’s patented two-step design streamlines the process of testing for common seasonal viruses (SARS-CoV-2, Influenza A, Influenza B, and RSV). Test by swabbing your nose, then placing the pen into its buffer cap, and reading results in 15 minutes. No need for extra components, or mixing reagents: it’s as easy as that.

Biolink can help your business save money and time with our range of rapid antigen tests.

Contact us

Two-step procedure

STEP 1. Remove the protector and insert the nasal collector into a nostril. Rotate the collector 5 times against the nasal wall. Repeat in other nostril.

STEP 2. Place the test device vertically into the tube with the extraction buffer. Ensure the top of the base aligns to the middle of the supporting line.

NOTE: Wait 15 minutes, then check your results. Do not read results after 30 minutes, as they will be invalid.

Results interpretation (COVID) 

COVID Positive

COVID Negative

Invalid

Results interpretation (RSV) 

RSV Positive

RSV Negative

Invalid

Results interpretation (Influenza A+B)

Influenza A
Positive

Influenza B
Positive

Influenza A+B
Positive

Influenza A+B Negative

Invalid

COVID, Influenza A+B & RSV test specifications

Assay formatLateral flow
TypePen
Testing time15 minutes to results; maximum 30 minutes
AntigenNucleocapsid protein (N)
Sample materialNasopharyngeal swab
ReagentsTBC

Clinical evaluation

COVID sensitivity97.0% (91.6% ~99.0%)
COVID specificity99.3% (98.1% ~99.8%)
Influenza A sensitivity94.3% (86.2% ~97.8%)
Influenza A specificity98.8% (97.3% ~99.4%)
Influenza B sensitivity93.9% (80.4% ~98.3%)
Influenza B specificity99.0% (97.8% ~99.6%)
RSV sensitivity 91.4% (77.6% ~97.0%)
RSV specificity98.8% (97.5% ~99.5%)

About Biolink

Global Clientele

International supplier of rapid antigen tests to government and multi-industry clients

End-to-end

Access to global supply networks and technologies to support your brand

Rapid & Reliable

Rapid and reliable shipping and logistics to support your network and supply chain

Versatile

Experts in at-home and point-of-care rapid testing across Europe, Australia, and North America

Easy

Straightforward ordering and distribution processes, with 24-hour global support channels

Safe

We work with specialists in user-friendly rapid antigen pens and cassettes for various diseases

Get in touch

Drop us a line. We'll get back to you as soon as we can.

More details

Made for convenience

Our pens are designed to be used in scenarios that don't allow for the easy mixing of reagents or buffer solutions. This makes it ideal for use in locations like schools, workplaces, day-cares, or hospitals, where it may be hard or inconvenient to perform a cassette style test. Just as quick and accurate as other RATs; but an easier, more comfortable user experience.

Summary of use

The COVID-19 & Influenza A+B & RSV Antigen Nasal Test Kit is an in-vitro immunoassay intended for the qualitative detection of antigens in nasal swab specimens from patients with COVID-19, and/or RSV (within first 7 days of symptom onset), and/or Influenza A+B (within first 4 days of symptom onset). This test doesn't discriminate between SARS-coronavirus and SARS-CoV-2 (COVID-19).

Precautions for use

The test is intended for point-of-care use; and not intended for home testing (or self-testing). It obtains a preliminary result only, to aid diagnosis of COVID-19, Influenza A+B, and RSV. Please note that negative results do not preclude viral infections—test results should not be the sole basis for treatment or other management decisions.